Overview of Oflocet 400

Oflocet 400 is a prescription-only synthetic antimicrobial agent defined by its active ingredient, ofloxacin. The product is designed for adults to combat systemic bacterial infections and is not used for viral illnesses. It functions as an anti-infective agent in clinical practice.

What Type of Medicine is Oflocet 400?

Oflocet 400 is classified as a fluoroquinolone antibiotic, specifically belonging to the family of second-generation quinolone drugs. The core chemical, ofloxacin, is a fluorinated carboxyquinolone that differs chemically from earlier antibiotics by its specific means of disrupting bacterial DNA. Oflocet 400 is utilized for its ability to target a wide spectrum of susceptible pathogens.

Oflocet 400: Active Ingredient and Formulation Details

The single active ingredient in Oflocet 400 is ofloxacin, which is chemically defined as a racemate. This means it consists of an equal mixture of two optical isomers, including levofloxacin. The product is manufactured as a 400 mg film-coated tablet designed for oral administration, making it a single-ingredient product. The tablet form ensures the precise amount of the active ingredient is delivered and distributed systemically to the site of the bacterial infection.

What Does "Broad-Spectrum Bactericidal" Mean for Oflocet?

Oflocet 400 is characterized by its bactericidal effect, meaning it kills susceptible bacteria rather than simply inhibiting their growth. This action works by blocking essential bacterial DNA replication processes, a characteristic mechanism of the fluoroquinolone class. The drug is considered broad-spectrum, granting it activity against a wide range of bacterial microorganisms, which defines its core therapeutic purpose.

Regulatory References

Ofloxacin - StatPearls - NCBI Bookshelf - NIH

What side effects are possible with Oflocet 400?

Regulatory Safety Profile of Oflocet 400 (Ofloxacin)

The possible side effects of Oflocet 400 are documented according to official regulatory classifications, detailing reactions by frequency and the body system affected. These classifications move from Common events to those that are Rare but clinically significant.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by System Organ Class (SOC) in regulatory documents, with frequency classifications often applied:

Common Reactions (may affect up to 1 in 10 people) typically involve Gastrointestinal Disorders such as nausea, vomiting, or diarrhea.
Uncommon Reactions (may affect up to 1 in 100 people) include certain Nervous System Disorders like dizziness and headache, and skin reactions such as rash.
Rare Reactions (may affect up to 1 in 1,000 people) involve more distinct systemic impacts, particularly within the psychiatric and musculoskeletal domains.

Serious Safety Concerns

Official prescribing information highlights specific serious adverse reactions associated with the fluoroquinolone class:

Musculoskeletal and Connective Tissue Disorders: Documented risks include tendinitis and tendon rupture, most frequently involving the Achilles tendon. These events may sometimes be delayed in onset and lead to long-term impairment.
Nervous and Psychiatric Disorders: Peripheral neuropathy has been documented, and in some cases, symptoms may be irreversible. Other serious effects include convulsions and psychotic reactions (including suicidal ideation).
Cardiovascular and Vascular Disorders: The medication is associated with the potential for QT interval prolongation and documented risks of aortic dissection and aortic aneurysm.

Population-Specific Safety Notes

Safety notes specify considerations for certain groups: Older adults are at a greater risk of experiencing tendon rupture. Patients with renal impairment may require specific monitoring due to the potential for drug accumulation. Diabetic patients are noted to have a risk of blood glucose disturbance, including severe hypoglycemia.

This framework defines the medicine's official risk profile, detailing potential reactions and specific safety constraints.

Overdose and Emergency Response

Oflocet 400 Overdose and when to seek help

Overdose with Oflocet 400 (ofloxacin) is formally documented in regulatory sources by specific clinical manifestations and mandated emergency actions.

Documented Clinical Manifestations

Overdose may present with central nervous system (CNS) effects, including convulsions, dizziness, confusion, and anxiety. Gastrointestinal manifestations such as nausea and vomiting have also been reported. Severe psychiatric events, notably acute psychotic reactions, may occur, sometimes after a single exposure.

Severe Outcomes and Emergency Actions

The official profile highlights the risk of life-threatening events, including cardiovascular issues like QTc prolongation and Torsade de pointes, and metabolic disturbances such as severe hypoglycemia, which is particularly noted in elderly or diabetic patients. Immediate medical attention or contacting emergency services is required for symptoms such as severe, sudden abdominal, chest, or back pain (potential aortic event). The medication must be discontinued immediately upon the first sign of severe reactions like persistent neuropathy symptoms or severe psychotic episodes.

Management and Monitoring

Management of overdose is officially described as symptomatic and supportive. Procedural measures such as gastric lavage are referenced. Additionally, monitoring of serum ofloxacin concentrations is specifically noted as necessary for patients with impaired renal function, reflecting a population-specific consideration in overdose management.

Therapeutic Uses of Oflocet 400

Quick Facts: Uses of Oflocet 400

Addresses: Acute bacterial exacerbations of chronic bronchitis
Manages: Community-acquired pneumonia
Provides Relief For: Certain skin and skin structure infections
Helps Resolve: Specific urinary tract infections (UTIs), including complicated cases
Supports Treatment Of: Acute pelvic inflammatory disease and prostatitis

Oflocet 400 (ofloxacin) is designated for the management of various bacterial infections in adults. Its authorized therapeutic domains involve addressing respiratory tract concerns, such as community-acquired pneumonia and acute exacerbations of chronic bronchitis. The medication also serves as a component of the management plan for infections of the skin and its underlying structures.

Furthermore, Oflocet 400 helps in the resolution of specific infections within the genitourinary system, including both uncomplicated and complicated urinary tract infections, as well as prostatitis caused by susceptible organisms. The drug also has a designated role in the treatment regimen for acute pelvic inflammatory disease.

Eligibility and Restrictions for Use

Who Can and Cannot Use Oflocet 400?

Oflocet 400 (ofloxacin) eligibility is strictly defined by regulatory documents, distinguishing between approved, restricted, and contraindicated populations.

Contraindicated Populations (Must Not Use)

Use of Oflocet 400 is contraindicated in several specific groups:

Hypersensitivity: Patients with a known allergy to ofloxacin, any other fluoroquinolone antibiotic, or the formulation's excipients.
Age: Children and growing adolescents whose skeletal growth is incomplete (typically under 18 years of age).
History: Individuals with a history of tendon disorders related to previous fluoroquinolone use.
Physiological State: Pregnant women and breastfeeding women.
Neurological Risk: Patients with a history of epilepsy or central nervous system disorders that may lower the seizure threshold.

Restricted or Conditional Use

Certain populations may use Oflocet 400 only with caution and often require dosage adjustment:

Organ Function: Patients with impaired renal function require a lower dosage due to reduced drug clearance. Patients with severe hepatic dysfunction must also be monitored closely.
Comorbidities: Caution is required for patients with risk factors for QT interval prolongation (e.g., existing cardiac disease) and those with Myasthenia Gravis.

What should I know about interactions with other medicines?

Oflocet 400 (ofloxacin) has documented interaction patterns with several medicines and substances, primarily affecting drug absorption, clearance, and pharmacodynamic effects, as detailed in regulatory documents.

Exposure-Altering Interactions

The absorption of Oflocet 400 is significantly reduced by chelation when co-administered with multivalent cation-containing products, including Antacids, Iron Salts, Sucralfate, and Multivitamins with Minerals. Official labeling mandates a timing separation requirement: these products must not be taken within 2 hours before or after Oflocet 400 to prevent reduced bioavailability. Certain foods, such as those high in calcium, and enteral feedings may also decrease serum concentrations.

Pharmacodynamic and Clearance Interactions

Oflocet 400 may reduce the degradation of co-administered drugs like Theophylline, Ciclosporin, Methotrexate, and Glibenclamide, leading to an increase in their plasma concentration. Co-administration with Oral Anticoagulants (e.g., Warfarin) can lead to an increase in coagulation parameters. Additive pharmacodynamic effects are documented with agents that prolong the QT interval (e.g., certain Antiarrhythmics and Macrolides), increasing risk. Additionally, combining ofloxacin with NSAIDs (e.g., Fenbufen) or Theophylline may potentiate the risk of central nervous system toxicity by lowering the cerebral seizure threshold. In Elderly Patients, the risk of QTc prolongation interactions is noted to be heightened.

Mechanism of Action

Molecular Targets in Bacterial DNA Management

Oflocet 400 (Ofloxacin) acts as an inhibitor and a topoisomerase poison by specifically targeting two essential bacterial enzymes: DNA gyrase and Topoisomerase IV. These enzymes are critical for managing the physical structure of the bacterial chromosome during cell maintenance and replication. By binding to these targets, Ofloxacin blocks the processes of DNA unwinding and chromosome separation, which are required for cell survival.

Cascade Leading to Bactericidal Effect

The inhibition of these DNA-managing enzymes initiates a rapid and destructive mechanistic cascade. The drug stabilizes a cleaved intermediate complex, converting the enzymes into agents that actively create irreparable, double-strand DNA breaks throughout the bacterial genome. This irreversible damage to the genetic material triggers the immediate cessation of bacterial replication and leads to the bactericidal physiological effect, which actively reduces the microbial population.

️ Constraints and Mechanism Limitations

The physiological consequence of this mechanism is dependent on the continued susceptibility of the bacterial targets. Resistance can emerge if the bacteria develop mutations in the enzyme's binding site or if they activate efflux pumps—molecular transporters that actively transport Ofloxacin out of the cell. These mechanisms reduce the necessary intracellular drug concentration, constraining the ability of the drug to inhibit the targets and achieve its full mechanistic consequence.

Dosage and Administration Information

Oflocet 400 is strictly designated for oral administration using the film-coated tablet formulation. The drug is prescribed for adult patients, with dosage determined by the healthcare professional based on the specific infection being managed. The general adult dosing range falls between 200 mg and 800 mg per day. Doses up to 400 mg may be taken as a single dose once daily, preferably in the morning. If the total daily dose exceeds 400 mg, it must be divided and administered in two separate doses.

The tablets must be swallowed whole with sufficient liquid and may be taken with or without food. A critical administration constraint is the requirement to separate the intake of Oflocet from mineral-containing preparations such as antacids, sucralfate, or supplements containing iron, zinc, aluminum, or magnesium. These products must not be taken within two hours of Oflocet to prevent interference with drug absorption.

Treatment duration is highly dependent on the diagnosis, ranging from a single day up to a maximum course of two months. Clinical guidelines mandate dosage modifications for adults with renal impairment or severe hepatic dysfunction. If a scheduled dose is missed, patients should take it immediately unless it is almost time for the next dose, in which case the missed dose must be skipped without doubling the subsequent amount.

Recent Clinical Evidence

Research evidence / Overview of studies for Oflocet 400

This section provides an overview of the research that regulators and scientists rely on when evaluating Oflocet 400 (ofloxacin). The evidence highlights what has been observed so far in clinical studies, what areas were examined, and what remains uncertain. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Evidence for Use in Respiratory and Urinary Infections

Research examined the use of Oflocet 400 in conditions such as Community-Acquired Pneumonia (CAP) and Complicated Urinary Tract Infections (cUTI). Studies included Randomized Controlled Trials (RCTs) and comparative trials. For CAP, research monitored outcomes related to systemic imbalance and the eradication of common pathogens. For cUTI and Prostatitis, research examined outcomes linked to inflammatory states, focusing on bacteriologic clearance and patient-reported outcomes describing perceived discomfort. Research describes patterns observed in bacteriologic clearance over defined time intervals, particularly for infections requiring longer treatment durations.

Limitations and Uncertainties

Research has explored short-term symptom changes, but there is limited information for long-term outcomes or recurrence rates after treatment cessation for most indications. A primary limitation is that many of the original efficacy studies were conducted before current widespread regulatory advisories regarding the risk profile of this class of medicine, which now restrict its use for certain common and uncomplicated conditions, such as Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) and Certain Skin Infections.

Furthermore, evolving bacterial resistance patterns are a concern; resistance in specific pathogens (like E. coli and N. gonorrhoeae) may affect the current applicability of older research. The research base primarily focuses on adult populations, and comparative evidence for certain groups, like those with multiple chronic conditions, is often insufficient.

Frequently Asked Questions (FAQ)

Common questions about Oflocet 400 (FAQ)

Q: What is Oflocet 400 used for?

A: Oflocet 400 is an antibiotic medication. It is approved for use in treating specific bacterial infections in different parts of the body, based on the specific prescribing information.

Q: Should Oflocet 400 be taken with food?

A: The official product information generally advises that Oflocet 400 can be taken with or without food. Specific guidance on how to take this medication should be clarified by the prescribing healthcare provider.

Q: How long does it take for Oflocet 400 to start working?

A: Like many antibiotics, the time required to observe improvement can vary widely depending on the type and severity of the infection. A healthcare provider is best suited to discuss the expected timeframe for symptom relief for a specific condition.

Q: What are the common side effects of Oflocet 400?

A: Common side effects reported in clinical trials may include nausea, headache, or dizziness. However, it is important to consult the official product labeling for a complete list and to discuss any specific concerns with a healthcare professional.

Q: Is Oflocet 400 safe during pregnancy?

A: Pregnant individuals should always consult their healthcare provider before taking Oflocet 400. Use during pregnancy is generally considered only when the potential benefit is thought to outweigh the potential risk, as determined by a qualified health professional.

How should Oflocet 400 be stored and disposed of?

How to Store and Dispose of Oflocet 400

The official storage and disposal guidelines for Oflocet 400 are documented to ensure product stability and safety. The medication must be kept in its closed container at room temperature. It is essential to protect the medicine from heat, freezing, moisture, and direct light.

For safety, the medicine must be secured out of the reach of children.

Regarding disposal, it is required that outdated or unneeded medicine not be kept. Patients should consult their healthcare professional for the proper disposal method, such as a drug take-back program. If a program is unavailable, unused medicine should be mixed with an unappealing substance (like used coffee grounds), placed in a sealed bag, and then put in the trash, ensuring that pills are not crushed.

Oflocet 400